Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ACHN Maxim Remains Bullish On Achillion Pharmaceuticals, Sees 59% Upside http://www.smarteranalyst.com/2014/11/17/maxim-remains-bullish-on-achillion-pharmaceuticals-sees-59-upside/
$CLDX UPDATE: Brean Capital Maintains Buy On Celldex Therapeutics Following Positive Avastin-Naïve Data http://www.smarteranalyst.com/2014/11/17/update-brean-capital-maintains-buy-on-celldex-therapeutics-following-positive-avastin-naive-data/
$CLDX UPDATE: Brean Capital Maintains Buy On Celldex Therapeutics Following Positive Avastin-Naïve Data http://www.smarteranalyst.com/2014/11/17/update-brean-capital-maintains-buy-on-celldex-therapeutics-following-positive-avastin-naive-data/
$INO UPDATE: Maxim Comments On Inovio Following Termination Of Agreement With Roche http://www.smarteranalyst.com/2014/11/17/update-maxim-comments-on-inovio-following-termination-of-agreement-with-roche/
$IMUC Roth Capital Reiterates Buy On ImmunoCellular Following Presentation Of An Updated Phase 2 ICT-107 Data http://www.smarteranalyst.com/2014/11/17/roth-capital-reiterates-buy-on-immunocellular-following-presentation-of-updated-phase-2-ict-107-data/
$IAG Roth Capital Maintains Buy On IAMGOLD Following Q3:14 Financial Results http://www.smarteranalyst.com/2014/11/17/roth-capital-maintains-buy-on-iamgold-following-q314-financial-results/
$IAG Roth Capital Maintains Buy On IAMGOLD Following Q3:14 Financial Results http://www.smarteranalyst.com/2014/11/17/roth-capital-maintains-buy-on-iamgold-following-q314-financial-results/
$FB 4 Key Takeaways From Topeka's Note On Facebook Following Mid-Quarter Ad Checks With Ampush http://www.smarteranalyst.com/2014/11/17/4-key-takeaways-from-topekas-note-on-facebook-following-mid-quarter-ad-checks-with-ampush/
$FB 4 Key Takeaways From Topeka's Note On Facebook Following Mid-Quarter Ad Checks With Ampush http://www.smarteranalyst.com/2014/11/17/4-key-takeaways-from-topekas-note-on-facebook-following-mid-quarter-ad-checks-with-ampush/
$CPRX Roth Capital Maintains Buy On Catalyst Pharmaceutical Following 3Q14 Update http://www.smarteranalyst.com/2014/11/17/roth-capital-maintains-buy-on-catalyst-pharmaceutical-following-3q14-update/
Oppenheimer Cuts Tripadvisor Price Target As "InstaBook" Does Not Equal "InstaResults http://www.smarteranalyst.com/2014/11/17/oppenheimer-cuts-tripadvisor-price-target-as-instabook-does-not-equal-instaresults/
$CLDX Celldex Remains Undervalued As Rindopepimut Remains Unappreciated, Says Oppenheimer http://www.smarteranalyst.com/2014/11/17/celldex-remains-undervalued-as-rindopepimut-remains-unappreciated-says-oppenheimer/
$CLDX Celldex Remains Undervalued As Rindopepimut Remains Unappreciated, Says Oppenheimer http://www.smarteranalyst.com/2014/11/17/celldex-remains-undervalued-as-rindopepimut-remains-unappreciated-says-oppenheimer/
$LINE Linn Energy: MLV Remains On The Sidelines; Reiterates Hold http://www.smarteranalyst.com/2014/11/14/linn-energy-mlv-remains-on-the-sidelines-reiterates-hold/
$HAL $BHI Halliburton Is In Talks To Acquire Baker Hughes; Deutsche Bank Comments http://www.smarteranalyst.com/2014/11/14/halliburton-is-in-talks-to-acquire-baker-hughes-deutsche-bank-comments/
$HAL $BHI Halliburton Is In Talks To Acquire Baker Hughes; Deutsche Bank Comments http://www.smarteranalyst.com/2014/11/14/halliburton-is-in-talks-to-acquire-baker-hughes-deutsche-bank-comments/
$OLED Oppenheimer Steps To The Sidelines On Universal Display http://www.smarteranalyst.com/2014/11/14/oppenheimer-steps-to-the-sidelines-on-universal-display/
$XONE ExOne: Stock Action Following A Poor 3Q14 Suggests Downside Washing Out, Says Oppenheimer http://www.smarteranalyst.com/2014/11/14/exone-stock-action-following-a-poor-3q14-suggests-downside-washing-out-says-oppenheimer/
$YHOO Oppenheimer Raised Yahoo! Price Target On The Back Of Higher BABA Valuation http://www.smarteranalyst.com/2014/11/14/oppenheimer-raised-yahoo-price-target-on-the-back-of-higher-baba-valuation/
$YHOO Oppenheimer Raised Yahoo! Price Target On The Back Of Higher BABA Valuation http://www.smarteranalyst.com/2014/11/14/oppenheimer-raised-yahoo-price-target-on-the-back-of-higher-baba-valuation/
$HIMX Himax Quarterly Update; Oppenheimer Reiterates Outperform http://www.smarteranalyst.com/2014/11/14/himax-quarterly-update-oppenheimer-reiterates-outperform/
$OXGN MLV Reiterates Buy On Oxigene In Light Of FDA Approval Of Genentech’s Bevacizumab http://www.smarteranalyst.com/2014/11/14/mlv-reiterates-buy-on-oxigene-in-light-of-fda-approval-of-genentechs-bevacizumab/
$INVN InvenSense: Expects Risks To Outweigh Long-Term Potential, Says Oppenheimer http://www.smarteranalyst.com/2014/11/14/invensense-expects-risks-to-outweigh-long-term-potential-says-oppenheimer/
$GERN MLV Maintains Buy On Geron Following Collaboration Agreement With Janssen http://www.smarteranalyst.com/2014/11/14/mlv-maintains-buy-on-geron-following-collaboration-agreement-with-janssen/
$GERN MLV Maintains Buy On Geron Following Collaboration Agreement With Janssen http://www.smarteranalyst.com/2014/11/14/mlv-maintains-buy-on-geron-following-collaboration-agreement-with-janssen/
$GRPN William Blair Maintains Market Perform On Groupon Following Its First Analyst Day http://www.smarteranalyst.com/2014/11/14/william-blair-maintains-market-perform-on-groupon-following-its-first-analyst-day/
$GRPN William Blair Maintains Market Perform On Groupon Following Its First Analyst Day http://www.smarteranalyst.com/2014/11/14/william-blair-maintains-market-perform-on-groupon-following-its-first-analyst-day/
$IMUC Maxim Maintains Buy On ImmunoCellular Following 3Q14 Update http://www.smarteranalyst.com/2014/11/14/maxim-maintains-buy-on-immunocellular-following-3q14-update/
$NBS Maxim Assumes Buy On Neostem Ahead Of Data Release At AHA Annual Meeting http://www.smarteranalyst.com/2014/11/14/maxim-assumes-buy-on-neostem-ahead-of-data-release-at-aha-annual-meeting/
$WMT William Blair Remains Bearish On Wal-Mart Shares Due To Secular Concerns http://www.smarteranalyst.com/2014/11/14/william-blair-remains-bearish-on-wal-mart-shares-due-to-secular-concerns/
$WMT William Blair Remains Bearish On Wal-Mart Shares Due To Secular Concerns http://www.smarteranalyst.com/2014/11/14/william-blair-remains-bearish-on-wal-mart-shares-due-to-secular-concerns/
$EXXI MLV Reiterates Hold On Energy XXI Following Fiscal Q1:15 Earnings http://www.smarteranalyst.com/2014/11/14/mlv-reiterates-hold-on-energy-xxi-following-fiscal-q115-earnings/
$CYBR William Blair Reiterates Outperform On CyberArk Following Impressive First Quarter As A Public Company http://www.smarteranalyst.com/2014/11/14/william-blair-reiterates-outperform-on-cyberark-following-impressive-first-quarter-as-a-public-company/
$CYBR William Blair Reiterates Outperform On CyberArk Following Impressive First Quarter As A Public Company http://www.smarteranalyst.com/2014/11/14/william-blair-reiterates-outperform-on-cyberark-following-impressive-first-quarter-as-a-public-company/
$ASTM Maxim Group Maintains Cautious Stance On Aastrom Following 3Q14 Update http://www.smarteranalyst.com/2014/11/14/maxim-group-maintains-cautious-stance-on-aastrom-following-3q14-update/
$GALE Roth Capital Comments On Galena Biopharma As Herceptin Combo Starts As Expected http://www.smarteranalyst.com/2014/11/14/roth-capital-comments-on-galena-biopharma-as-herceptin-combo-starts-as-expected/
$LGND $GSK Roth Capital Comments On Ligand Following EMA Submission For Revolade http://www.smarteranalyst.com/2014/11/14/roth-capital-comments-on-ligand-following-ema-submission-for-revolade/
$STML Roth Capital Reiterates Buy On Stemline Following 3Q14 Results http://www.smarteranalyst.com/2014/11/14/roth-capital-reiterates-buy-on-stemline-following-3q14-results/
$TNXP Roth Capital Reiterates Buy On Tonix Pharmaceuticals As Risk-Reward Is Favorable http://www.smarteranalyst.com/2014/11/14/roth-capital-reiterates-buy-on-tonix-pharmaceuticals-as-risk-reward-is-favorable/
$XOMA Roth Capital Reiterates Buy On Xoma Following 3Q:14 Update http://www.smarteranalyst.com/2014/11/14/roth-capital-reiterates-buy-on-xoma-following-3q14-update/